[ad_1]
The corporate has constructed an end-to-end AI-based platform that comprehensively maps the course of a illness on the protein stage.
Israeli AI-powered drug discovery firm Protai right this moment introduced the completion of an $8 million seed financing spherical co-led by Grove Ventures and Pitango HealthTech. The corporate mentioned that the brand new funding shall be used to develop its platform, speed up its discovery packages and improve partnerships with pharmaceutical corporations.
Protai, which was solely based final 12 months, has constructed an end-to-end AI-based platform that comprehensively maps the course of a illness on the protein stage, enhancing the power to look at mobile perform and thereby bettering the best way new medicine are found. This strategy permits Protai to extend accuracy in drug discovery and enhance the event course of, considerably saving time and reducing the prices of R&D.
Protai cofounder and CEO Eran Seger mentioned, “Protai’s platform is sort of a distinctive compass for steering drug discovery. We’re systematically mapping ailments on the protein stage to create a completely new layer of purposeful data which allows us to determine therapeutic and diagnostic targets to raised fight a variety of advanced ailments.”
Protai claims to have created the world’s largest and most various proteomic database with over 50,000 medical samples by harmonizing giant medical datasets, in addition to wholesome samples from varied organs and indications. This allows Protai to ascertain a baseline to then precisely simulate organic purposeful processes for a wide range of ailments and speed up drug R&D by medical and preclinical phases.
Revealed by Globes, Israel enterprise information – en.globes.co.il – on January 5, 2022.
© Copyright of Globes Writer Itonut (1983) Ltd., 2022.
Portai crew Picture: David Karp
[ad_2]
Source link
